Feedback

Browsing by B


Use an asterisk (*) for partial word searches (e.g. pemph*)

162 results found.

1.
2.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
3.
Ordering Recommendation:   Used primarily to monitor response to rituximab therapy.
4.
5.
Ordering Recommendation:   Assess B-cell subsets in immunodeficiencies, such as common variable immunodeficiency or B-cell reconstitution after bone marrow or hematopoietic stem cell transplantation. Not recommended for Rituximab monitoring, refer to B-Cell CD20 Expression (0092099).
6.
Ordering Recommendation:   Aids in diagnosis, prognosis, and management of acute and chronic heart failure.
7.
Ordering Recommendation:   May be useful in patients for whom babesiosis is highly suspected, yet B. microti testing is negative and patient has a recent history of West Coast travel with possible exposure to ticks.
8.
Ordering Recommendation:   Useful if Giemsa stain is negative but high suspicion of babesiosis exists. Will not detect B. duncani or strain MO-1.
9.
Ordering Recommendation:   Refer to Babesia microti Antibodies, IgG and IgM by IFA (0093048) panel, which includes IgG and IgM by IFA.
10.
Ordering Recommendation:   Refer to Babesia microti Antibodies, IgG and IgM by IFA (0093048) panel, which includes IgG and IgM by IFA.
11.
Ordering Recommendation:   First-line test for diagnosing acute babesiosis. This PCR test detects nucleic acid from B. microti and detects but does not differentiate between B. duncani, B. divergens, strain MO-1, and strain EU-1. Blood smears are also appropriate for diagnosing and monitoring babesiosis disease; refer to Parasites Smear (Giemsa Stain), Blood (0049025).
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Ordering Recommendation:   May confirm a current or past exposure to B. henselae or B. quintana in patient with typical signs and symptoms and a compatible exposure history.
22.
Ordering Recommendation:   May assist in diagnosing cat scratch disease in patient with typical signs and symptoms and a compatible exposure history.
23.
Ordering Recommendation:   May assist in confirming a current or past Bartonella henselae infection.
24.
Ordering Recommendation:   May assist in confirming an early or recent Bartonella henselae infection.
25.
Ordering Recommendation:   May assist in confirming suspected Trench fever in patient with typical signs and symptoms and compatible exposure history.
26.
Ordering Recommendation:   May assist in confirming suspected Trench fever in patient with typical signs and symptoms and compatible exposure history.
27.
Ordering Recommendation:   May assist in confirming suspected Trench fever in patient with typical signs and symptoms and compatible exposure history.
28.
29.
30.
31.
32.
33.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
34.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
35.
Ordering Recommendation:   Sensitive method for detecting MYC rearrangement in FFPE.
36.
Ordering Recommendation:   Determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). Test detects all common mutations, including T315I.
37.
Ordering Recommendation:   This quantitative test is appropriate for diagnosis and therapeutic monitoring for CML or ALL. The BCR-ABL1 major (p210) fusion forms are present in almost all cases of CML and in a small subset of cases of ALL
38.
Ordering Recommendation:   Order in cases of Philadelphia chromosome positive (Ph+) lymphoblastic leukemia to quantify the BCR-ABL1 p190 fusion form. For CML, use BCR-ABL1, Major (p210), Quantitative, (2005017).
39.
Ordering Recommendation:   For use in detecting the presence of a BCR-ABL1 fusion, for determining breakpoint status, and for baseline quantitation.
40.
Ordering Recommendation:   Aids in the workup of plasma cell dyscrasia. Use to detect and quantify urinary free light chains (Bence Jones protein).
41.
42.
43.
44.
45.
46.
47.
Ordering Recommendation:   Recommended test for identifying beryllium sensitization and chronic beryllium disease (CBD). Use in asymptomatic individuals with chronic exposure to beryllium or in symptomatic individuals with a history of beryllium exposure.
48.
Ordering Recommendation:   Confirm an exposure to beryllium but NOT useful indicator for determining time since exposure or the extent of an exposure. Refer to Beryllium Lymphocyte Proliferation Test (2011052) for a more reliable indicator of beryllium sensitization and/or Chronic Beryllium Disease (CBD).
49.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the combined sequencing and deletion/duplication test.
50.
Ordering Recommendation:   Molecular confirmation of a suspected structural hemoglobinopathy or beta thalassemia.
51.
Ordering Recommendation:   Order to confirm suspected HbS, HbC, and HbE mutations.
52.
Ordering Recommendation:   Genetic test on fetal samples for prenatal detection of HbS, HbC, and HbE mutations.
53.
Ordering Recommendation:   Preferred test for molecular confirmation of beta thalassemia or a hemoglobinopathy involving the beta-globin gene.
54.
Ordering Recommendation:   Confirmatory genetic test on fetal samples for the prenatal detection of structural hemoglobinopathies and beta thalassemia.
55.
Ordering Recommendation:   Acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected. Order with lupus anticoagulant (LA) (0030181) and anticardiolipin (aCL) IgG and IgM (0099344) assays.
56.
57.
Ordering Recommendation:   Preferred second-line testing for patients considered seronegative antiphospholipid syndrome (APS). Order incrementally or concurrently with other non-criteria antiphospholipid antibody tests.
58.
59.
Ordering Recommendation:   Use for risk stratification and staging of multiple myeloma, Waldenstrom macroglobulinemia, and other lymphoproliferative disorders. Aids in differentiating glomerular and tubular renal disease.
60.
61.
Ordering Recommendation:   This test is for clinical research purposes only. Please call Genetics at 800-242-2782 extension 2956 to arrange for research collaboration.
62.
63.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
64.
65.
66.
67.
68.
69.
70.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
71.
72.
Ordering Recommendation:   Do not use to diagnose liver dysfunction. Use to screen for inborn errors of bile acid metabolism or monitor bile acid therapy.
73.
Ordering Recommendation:   Use to detect hepatobiliary dysfunction. Do not order to detect inborn errors of bile acid metabolism. May aid in diagnosis of intrahepatic cholestasis of pregnancy.
74.
75.
76.
77.
78.
79.
Ordering Recommendation:   Molecular (DNA) test to confirm a diagnosis of biotinidase (BTD) deficiency when biotinidase enzymatic activity is low. Carrier testing for individuals with a family history of BTD deficiency when familial mutations are included in the 5 mutation panel. To diagnose or rule out BTD deficiency, refer to Biotinidase, Serum (with Paired Normal Control) (0093362).
80.
Ordering Recommendation:   Molecular (DNA) test to confirm a diagnosis of biotinidase (BTD) deficiency when biotinidase enzymatic activity is low. To diagnose or rule out BTD deficiency, refer to Biotinidase, Serum (with Paired Normal Control) (0093362).
81.
Ordering Recommendation:   Biotinidase enzyme test. Initial test to diagnose or rule out biotinidase deficiency.
82.
83.
84.
85.
86.
87.
88.
Ordering Recommendation:   This test is indicated for use as an aid in the management of bladder cancer patients in conjunction with cystoscopy. Qualitative assay detects bladder tumor associated antigen in urine of persons diagnosed with bladder cancer.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
Ordering Recommendation:   Diagnostic testing for Bloom syndrome. Carrier screening for Bloom syndrome.
100.
Ordering Recommendation:   Diagnostic testing for Bloom syndrome.
101.
102.
103.
104.
Ordering Recommendation:   Preferred test for molecular confirmation of hereditary bone marrow failure.
105.
106.
Ordering Recommendation:   CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117). However, if serology is used to assess late-stage pertussis (> than 4 weeks), this is the recommended test.
107.
Ordering Recommendation:   If serology is used to assess late-stage pertussis (> than 4 weeks), the recommended test is Bordetella pertussis Antibodies, IgA and IgG by ELISA with Reflex to Immunoblot (2001774). CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
108.
Ordering Recommendation:   If serology is used to assess late-stage pertussis (> than 4 weeks), the recommended test is Bordetella pertussis Antibodies, IgA and IgG by ELISA with Reflex to Immunoblot (2001774). CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
109.
Ordering Recommendation:   If serology is used to assess late-stage pertussis, the recommended test is Bordetella pertussis Antibodies, IgA and IgG by ELISA with Reflex to Immunoblot (2001774). CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
110.
Ordering Recommendation:   Not a stand-alone test. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117). If serology is used to assess late-stage pertussis, the recommended test is Bordetella pertussis Antibodies, IgA and IgG by ELISA with Reflex to Immunoblot (2001774).
111.
Ordering Recommendation:   In most cases, serology testing is not recommended for the diagnosis of active pertussis infection. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
112.
Ordering Recommendation:   In most cases, serology testing is not recommended for the diagnosis of active pertussis infection. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
113.
Ordering Recommendation:   If serology is used to assess late-stage pertussis, the recommended test is Bordetella pertussis Antibodies, IgA and IgG by ELISA with Reflex to Immunoblot (2001774). CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
114.
Ordering Recommendation:   Evaluation of IgM pertussis antibodies has little clinical utility. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
115.
Ordering Recommendation:   Evaluation of IgM pertussis antibodies has little clinical utility. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
116.
Ordering Recommendation:   CDC recommended test for the diagnosis of pertussis.
117.
Ordering Recommendation:   CDC recommended test for the diagnosis of pertussis. Consider concurrent testing with B. pertussis by PCR (0065080).
118.
Ordering Recommendation:   Not recommended for the diagnosis of pertussis due to low sensitivity. CDC first-line tests for pertussis are PCR (0065080) and/or culture (0060117).
119.
Ordering Recommendation:   CDC recommended test for the diagnosis of pertussis.
120.
121.
Ordering Recommendation:   Preferred CSF reflex panel for workup of suspected neuroborreliosis.
122.
Ordering Recommendation:   Do not order in the absence of a positive/equivocal ELISA screening test. IgM Western blot is not useful after the first 4 weeks of clinical symptoms.
123.
Ordering Recommendation:   Use in conjunction with positive serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.
124.
Ordering Recommendation:   First-line serologic screening test for suspected Lyme disease. Positive or equivocal results must be confirmed with a Western blot.
125.
Ordering Recommendation:   Preferred reflex test to detect Lyme disease in individuals with <=4 weeks of clinical symptoms or exposure to tick. Positive/equivocal screen confirmed by Western blot.
126.
Ordering Recommendation:   Use in conjunction with positive serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.
127.
Ordering Recommendation:   Do not order in the absence of a positive/equivocal ELISA screening test. During first 4 weeks of clinical symptoms, order concurrent IgM Western blot test.
128.
Ordering Recommendation:   Use in conjunction with positive serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.
129.
Ordering Recommendation:   Do not order in the absence of a positive/equivocal ELISA screening test. Useful only when ordered during first 4 weeks of clinical symptoms and concurrently with IgG Western blot test.
130.
Ordering Recommendation:   Use in conjunction with serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.
131.
Ordering Recommendation:   First-line serologic screening test for suspected Lyme disease. Positive or equivocal results must be confirmed with a Western blot.
132.
Ordering Recommendation:   Use in conjunction with positive serologic testing for the workup of suspected acute Lyme neuroborreliosis. Do not order in the absence of clinical symptoms.
133.
Ordering Recommendation:   Preferred reflex test to detect Lyme disease in individuals with <=4 weeks of clinical symptoms or exposure to tick. Positive/equivocal screen confirmed by Western blot.
134.
Ordering Recommendation:   Preferred reflex test to detect Lyme disease in individuals with >4 weeks of clinical symptoms or exposure to tick. Positive/equivocal screen confirmed by Western blot.
135.
Ordering Recommendation:   Preferred reflex test to detect Lyme disease in individuals with >4 weeks of clinical symptoms or exposure to tick. Positive/equivocal screen confirmed by Western blot.
136.
Ordering Recommendation:   Use for diagnostic workup of suspected tick-borne relapsing fever.
137.
Ordering Recommendation:   Not a first-line test for Lyme disease. May be useful if strong suspicion of Lyme disease persists in spite of persistent negative serologic testing.
138.
139.
Ordering Recommendation:   Evaluate suspected Lynch syndrome. Use to predict effectiveness of therapies targeting the EGFR pathway. Evaluate thyroid specimens (tissue blocks or formalin-fixed, paraffin-embedded cell blocks prepared from fine needle aspirates [FNA]) for BRAF mutations for purpose of diagnosis, prognosis, and possible therapeutics. For endometrial tissue evaluation, refer to MLH1 Promoter Methylation, Paraffin (2002499). For FNA direct smears, the preferred test is BRAF V600E Mutation Detection by Allele-Specific PCR, Fine Needle Aspirate (2006516).
140.
Ordering Recommendation:   Recommended reflex test for differentiating between LS and sporadic CRC in tumors showing loss of MLH1. If no BRAF mutation is detected, MLH1 promoter methylation is evaluated.
141.
Ordering Recommendation:   Molecular test for the detection of the BRAF V600E mutation in direct smear specimens from fine needle aspirate (FNA). For tissue block or formalin-fixed, paraffin-embedded cell blocks prepared from FNA, may use BRAF codon 600 Mutation Detection by Pyrosequencing (2002498).
142.
Ordering Recommendation:   Confirm a diagnosis of hairy cell leukemia (HCL) and monitor tumor burden.
143.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
144.
Ordering Recommendation:   Preferred first-tier genetic test for confirmation of hereditary breast and ovarian cancer (HBOC) syndrome.
145.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
146.
Ordering Recommendation:   To determine if there is a heritable predisposition for breast or ovarian cancer in adults with any of the following:()Breast cancer diagnosed at age 50 or younger()Ovarian cancer()Multiple primary breast cancers either in the same breast or opposite breast()Both breast and ovarian cancer()Male breast cancer()Triple-negative (estrogen receptor negative, progesterone receptor negative, and HER2/neu [human epidermal growth factor receptor 2] negative) breast cancer()Pancreatic cancer with breast or ovarian cancer in the same individual or on the same side of the family()Ashkenazi Jewish ancestry()Two or more relatives with breast cancer, one under age 50()Three or more relatives with breast cancer at any age
147.
Ordering Recommendation:   To determine if there is a heritable predisposition for breast or ovarian cancer in adults with any of the following:()Breast cancer diagnosed at age 50 or younger()Ovarian cancer()Multiple primary breast cancers either in the same breast or opposite breasts()Both breast and ovarian cancer()Male breast cancer()Triple-negative (estrogen receptor negative, progesterone receptor negative, and HER2/neu [human epidermal growth factor receptor 2] negative) breast cancer()Pancreatic cancer with breast or ovarian cancer in the same individual or on the same side of the family()Ashkenazi Jewish ancestry()Two or more relatives with breast cancer, one under age 50()Three or more relatives with breast cancer at any age
148.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
149.
Ordering Recommendation:   Monitor therapy or use when suspicion for bromide toxicity (eg, hyperchloremia with negative anion gap and altered mental status).
150.
151.
152.
153.
Ordering Recommendation:   Refer to Additional Technical Information document.
154.
Ordering Recommendation:   Initial screening for X-linked agammaglobulinemia.
155.
Ordering Recommendation:   ()Monitor disease in patient previously diagnosed with pemphigoid and increased antibodies for IgG BP180 and/or BP230; IgG BP180 antibody levels correlate with disease activity.()For initial diagnosis and assessment of disease progression or changes, the preferred test is the pemphigoid antibody panel (0092001); panel components include IgG and IgA epithelial BMZ antibodies and IgG bullous pemphigoid (BP 180 and 230) antigens.()To determine the involvement of IgG BMZ antibodies and pattern of reactivity on split skin substrate, order with antibody testing for IgG epithelial BMZ (0092056).()Also, consider other types of BMZ antibody-associated disease testing, (i.e., IgA epithelial BMZ (0092057), IgG collagen type VII (2010905), or herpes gestationis factor (0092283)).
156.
157.
158.
159.
160.
161.
162.